SARS-CoV-2 Omicron subvariants progressively adapt to human cells with altered host cell entry
mSphere · 2024
DOI: 10.1128/msphere.00338-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift mSphere, 2024. Verfasst von Yasuteru Sakurai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan. Hauptthemen laut MEDLINE: SARS-CoV-2, Virus Internalization, COVID-19, Spike Glycoprotein, Coronavirus. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MEXT | Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant exhibits high transmissibility with a strong immune escape ability and causes frequent large-scale global infections by producing predominant subvariants. Here, using human upper/lower airway and intestinal cells, we examined the previously dominant BA.1–BA.5 and BA.2.75 subvariants, together with the recently emerged XBB/BQ lineages, in comparison to the former Delta variant. We observed a tendency for each virus to demonstrate higher growth capability than the previously dominant subvariants. Unlike human bronchial and intestinal cells, nasal epithelial cells accommodated the efficient entry of certain Omicron subvariants, similar to the Delta variant. In contrast to the Delta’s reliance on cell-surface transmembrane protease serine 2, all tested Omicron variants depended on endosomal cathepsin L. Moreover, S1/S2 cleavage of early Omicron spikes was less efficient, whereas recent viruses exhibit improved cleavage efficacy. Our results show that the Omicron variant progressively adapts to human cells through continuous endosome-mediated host cell entry. IMPORTANCE SARS-CoV-2, the causative agent of coronavirus disease 2019, has evolved into a number of variants/subvariants, which have generated multiple global waves of infection. In order to monitor/predict virological features of emerging variants and determine appropriate strategies for anti-viral development, understanding conserved or altered features of evolving SARS-CoV-2 is important. In this study, we addressed previously or recently predominant Omicron subvariants and demonstrated the gradual adaptation to human cells. The host cell entry route, which was altered from the former Delta variant, was conserved among all tested Omicron subvariants. Collectively, this study revealed both changing and maintained features of SARS-CoV-2 during the Omicron variant evolution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.
- Department of Emerging Infectious Diseases, National Research Center for the Control and Prevention of Infectious Diseases (CCPID), Nagasaki University, Nagasaki, Japan.
- School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan.
- Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
ORCID-Profile: Yasuteru Sakurai, Jiro Yasuda
Förderung
- MEXT | Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
Zitieren
APA
Sakurai, Y., Okada, S., Ozeki, T., Yoshikawa, R., Kinoshita, T., & Yasuda, J. (2024). SARS-CoV-2 Omicron subvariants progressively adapt to human cells with altered host cell entry. mSphere. https://doi.org/10.1128/msphere.00338-24
Vancouver
Sakurai Y, Okada S, Ozeki T, Yoshikawa R, Kinoshita T, Yasuda J. SARS-CoV-2 Omicron subvariants progressively adapt to human cells with altered host cell entry. mSphere. 2024. doi:10.1128/msphere.00338-24
BibTeX
@article{Sakurai2024,
author = {Sakurai, Yasuteru and Okada, Sayaka and Ozeki, Takehiro and Yoshikawa, Rokusuke and Kinoshita, Takaaki and Yasuda, Jiro},
title = {SARS-CoV-2 Omicron subvariants progressively adapt to human cells with altered host cell entry},
journal = {mSphere},
year = {2024},
doi = {10.1128/msphere.00338-24}
}
EUVIMED